Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis During Treatment with Tofacitinib: A Case Report

In the case report from 2020, a male patient with psoriasis, psoriatic arthritis, and alopecia universalis (AU) experienced significant improvement in all three conditions after treatment with the oral Janus kinase (JAK) inhibitor tofacitinib. Initially, the patient's psoriasis was controlled with ciclosporin, and his psoriatic arthritis was managed with salazopyrine. However, he developed alopecia areata (AA), which progressed to AU despite treatment with ciclosporin and methotrexate. After starting tofacitinib at a dosage of 5 mg twice daily, the patient saw almost complete hair regrowth on the scalp and partial regrowth on the eyebrows, eyelashes, beard, and chest within 10 months. Additionally, his psoriasis nearly cleared, and he had no joint complaints, leading to the cessation of salazopyrine. This case suggests that JAK inhibitors like tofacitinib may be a viable treatment option for patients with concurrent dermatological and rheumatological diseases.